Literature DB >> 21728017

JAK inhibition in rheumatoid arthritis.

Aarat M Patel1, Daniel Lupash, Douglas Chew, Marc C Levesque, Larry W Moreland.   

Abstract

Entities:  

Year:  2011        PMID： 21728017     DOI： 10.1007/s11926-011-0196-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  2 in total

Review 1.  Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.

Authors:  Richard J Riese; Sriram Krishnaswami; Joel Kremer
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-08       Impact factor: 4.098

2.  Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

Authors:  J H Coombs; B J Bloom; F C Breedveld; M P Fletcher; D Gruben; J M Kremer; R Burgos-Vargas; B Wilkinson; C A F Zerbini; S H Zwillich
Journal:  Ann Rheum Dis       Date:  2009-07-08       Impact factor: 19.103
  2 in total
  1 in total

1.  BD750, a benzothiazole derivative, inhibits T cell proliferation by affecting the JAK3/STAT5 signalling pathway.

Authors:  Y Liu; T Yang; H Li; M-H Li; J Liu; Y-T Wang; S-X Yang; J Zheng; X-Y Luo; Y Lai; P Yang; L-M Li; Q Zou
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.